# SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

> **NCT01962441** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 601 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** SOF
- **DRUG:** RBV
- **DRUG:** Peg-IFN

## Key facts

- **NCT ID:** NCT01962441
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-24
- **Primary completion:** 2015-01-07
- **Final completion:** 2016-07-07
- **Target enrollment:** 601 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01962441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01962441, "SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01962441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*